SK Bioscience Applies for Additional Indication of Novavax for Adolescents Aged 12-17
[Asia Economy Reporter Minji Lee] SK Bioscience announced on the 7th that it has applied to the Ministry of Food and Drug Safety for a change in the domestic approval of the Novavax COVID-19 vaccine. This is for the addition of an indication for adolescents aged 12 to 17.
Previously, in a clinical trial conducted in the United States targeting adolescents aged 12 to under 18, the vaccine showed approximately 79.5% efficacy, which is similar to the COVID-19 prevention effect in adults. The trial was conducted during the period when the Delta variant was dominant, and the prevention efficacy against the Delta variant was about 82%.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company explained, “After adding the adolescent indication, we expect to increase the vaccination rate among adolescents, which currently remains at around 60%, and to protect the safety of all age groups including adolescents.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
